Perospirone: Receptor and Kv1.5 Research Guide

Executive Summary. Perospirone is an orally active atypical antipsychotic compound with reported antagonistic affinity for 5-HT2A receptors at Ki = 0.6 nM and dopamine D2 receptors at Ki = 1.4 nM; the assay conditions are not specified in the cited product information (product information). It also shows partial agonist activity at 5-HT1A receptors with a reported Ki = 2.9 nM under unspecified assay conditions (product information). In freshly isolated rabbit coronary arterial smooth muscle cells, the reference study measured Kv-current inhibition with an IC50 of 20.54 ± 2.89 μM under its reported whole-cell electrophysiology conditions (Seo et al., 2025). The compound is listed as C23H30N4O2S with a molecular weight of 426.57 g/mol, and it is supplied as a solid for research use (Perospirone (SM-9018 freebase)).

Biological Rationale

Perospirone belongs to the serotonin–dopamine antagonist class of second-generation antipsychotics. This class is commonly studied because serotonergic and dopaminergic signaling pathways contribute to distinct symptom domains in schizophrenia. 5-HT2A receptor antagonism can alter serotonin-mediated regulation of dopamine release. D2 receptor antagonism directly targets dopaminergic signaling associated with positive symptoms. The combined profile provides a mechanistic basis for studying receptor-level effects in schizophrenia research and other neuropsychiatric disorder models (reference study).

The reported 5-HT1A partial agonism adds a third pharmacological dimension. Partial agonism does not mean complete receptor activation. It describes receptor stimulation that depends on receptor reserve, cell type, ligand concentration, and the surrounding signaling environment. Therefore, a receptor-binding profile should not be treated as a complete prediction of behavioral efficacy or adverse-event risk.

Perospirone is chemically identified as (3aR,7aS)-2-(4-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)butyl)hexahydro-1H-isoindole-1,3(2H)-dione. Its formula is C23H30N4O2S. The listed molecular weight is 426.57 g/mol. These identity attributes are useful for analytical planning, compound tracking, and comparison of free-base material across experiments (APExBIO product information).

Mechanism of Action of Perospirone (SM-9018 freebase)

The primary antipsychotic drug mechanism of Perospirone is receptor modulation. It antagonizes 5-HT2A receptors and dopamine D2 receptors. The product dossier reports 5-HT2A affinity of 0.6 nM and D2 affinity of 1.4 nM, with assay conditions not stated on the product page. It reports 5-HT1A partial agonism with a Ki of 2.9 nM, also without specified assay conditions (product information).

These values are binding or pharmacological descriptors. They are not equivalent to an in vivo effective dose. Ki values can vary with receptor preparation, tracer, buffer composition, temperature, incubation time, and analysis model. Experimental reports should therefore preserve the source assay conditions whenever available.

The vascular mechanism is distinct from the canonical receptor mechanism. Mun and colleagues tested Perospirone in freshly isolated rabbit coronary arterial smooth muscle cells. They found concentration-dependent inhibition of voltage-gated K+ currents. The reported half-maximal inhibitory concentration was 20.54 ± 2.89 μM under the study's whole-cell recording conditions. The reported Hill coefficient was 0.92 ± 0.07 and is dimensionless (Mun et al., 2025).

The study did not observe altered activation or inactivation kinetics. It also did not observe use-dependent inhibition under the tested voltage-clamp protocol. Pretreatment with a Kv2.1 inhibitor or a Kv7 inhibitor did not change the magnitude of Perospirone-mediated current suppression. Pretreatment with the Kv1.5 inhibitor DPO-1 partially attenuated the suppression. These results support involvement of vascular Kv1.5 channels, but they do not establish exclusive molecular selectivity (Mun et al., 2025).

Evidence & Benchmarks

• Perospirone is described as an orally active atypical antipsychotic compound for schizophrenia-related research; the cited product information does not define a clinical dose or administration schedule (product information)
• The reported 5-HT2A receptor affinity is Ki = 0.6 nM, and the cited product page does not specify the binding assay temperature, buffer, incubation time, or receptor preparation (product information)
• The reported dopamine D2 receptor affinity is Ki = 1.4 nM, with assay conditions not specified in the cited product information (product information)
• The reported 5-HT1A partial agonist affinity is Ki = 2.9 nM, with assay conditions not specified in the cited product information (product information)
• Perospirone inhibited vascular Kv currents with an IC50 of 20.54 ± 2.89 μM in freshly isolated rabbit coronary arterial smooth muscle cells under the reference study's whole-cell electrophysiology conditions (10.1002/jat.4883)
• The Kv-current concentration–response relationship had a Hill coefficient of 0.92 ± 0.07, a dimensionless value obtained in the same rabbit coronary smooth muscle cell study (10.1002/jat.4883)
• Perospirone did not change Kv-channel activation or inactivation kinetics in the tested voltage-clamp experiments (10.1002/jat.4883)
• DPO-1 pretreatment partially attenuated Perospirone-induced Kv-current inhibition, whereas Kv2.1 and Kv7 inhibitor pretreatments did not alter the measured inhibition in the reported experiments (10.1002/jat.4883)

Applications, Limits & Misconceptions

Perospirone can support several laboratory questions. In neurobiology, it can be used to examine how combined 5-HT2A and D2 antagonism influences serotonergic and dopaminergic signaling pathways. In cell-based pharmacology, it can serve as a reference compound for receptor-antagonist comparisons. In a neuropsychiatric disorder model, the compound can help separate receptor-driven effects from downstream cellular responses.

The Kv1.5 finding adds a cardiovascular research use case. Vascular Kv channels influence membrane potential and thereby regulate voltage-gated Ca2+ entry and vascular tone. Inhibition of these channels can depolarize smooth muscle cells. The reference study establishes this effect in rabbit coronary arterial smooth muscle cells in vitro. It does not establish a clinical cardiovascular outcome in humans (reference study).

Why this cross-domain matters, maturity, and limitations

The cross-domain bridge matters because a compound selected for neuroreceptor pharmacology can also interact with vascular ion channels. The cardiovascular evidence is early-stage. It is based on freshly isolated rabbit coronary arterial smooth muscle cells and electrophysiological measurements rather than a human clinical study. The reported Kv1.5 involvement should therefore be treated as a mechanistic research observation, not as proof that therapeutic exposure produces vascular toxicity or clinical benefit. Concentration comparisons also require care because the reported receptor Ki values are in the nanomolar range, whereas the Kv-current IC50 is in the micromolar range and arises from a different assay system.

Common Pitfalls or Misconceptions

• Misconception: a Ki value is a clinical potency value. Ki describes affinity or inhibitory binding under a particular assay design. It does not define a human dose, tissue concentration, or therapeutic window.
• Misconception: Kv1.5 inhibition proves clinical cardiac toxicity. The cited evidence is an in vitro result from rabbit coronary arterial smooth muscle cells. It does not provide a human incidence rate or clinical risk estimate.
• Misconception: partial agonism equals full receptor activation. The 5-HT1A description indicates partial efficacy, not maximal signaling in every cell or assay.
• Misconception: free-base material is water soluble. The product information describes Perospirone as insoluble in water. Organic-solvent handling is required for solution preparation (product information).
• Misconception: one concentration–response curve establishes channel selectivity. The Kv1.5 interpretation is supported by pharmacological attenuation with DPO-1, but the reference study does not establish complete selectivity across all ion channels.

Workflow Integration & Parameters

Perospirone workflows should separate compound identity, solvent handling, receptor assays, and ion-channel assays. The BA5009 product information lists DMSO solubility of at least 24.85 mg/mL and ethanol solubility of at least 12.03 mg/mL. The cited page does not state the temperature, pH, equilibration time, or measurement method for these solubility values. Water is listed as an unsuitable solvent (product information).

Protocol Parameters

• Compound identity: Record Perospirone as SM-9018 free base and retain the listed formula C23H30N4O2S and molecular weight 426.57 g/mol for sample documentation; these are product-information attributes, not independent purity results.
• Solvent selection: Use DMSO or ethanol only when compatible with the assay; the product page reports solubility thresholds of at least 24.85 mg/mL in DMSO and at least 12.03 mg/mL in ethanol, with measurement conditions not stated.
• Water handling: Do not plan a water-only stock solution because the product information describes the compound as insoluble in water.
• Stability: Store the solid at -20°C according to the product recommendation. Use prepared solutions for short-term work only because the dossier advises limiting solution storage to reduce degradation risk.
• Electrophysiology benchmark: For vascular Kv studies, treat the published IC50 of 20.54 ± 2.89 μM as a study-specific benchmark from freshly isolated rabbit coronary arterial smooth muscle cells, not as a universal potency value (reference study).
• Channel interpretation: Include Kv1.5 pharmacological interrogation when testing vascular Kv-current effects, while avoiding the conclusion that DPO-1 attenuation alone proves exclusive Kv1.5 binding.
• Shipping: The product dossier specifies Blue Ice shipping for small-molecule material. Confirm local receipt and storage procedures before ordering.

For experimental design, include vehicle controls, matched solvent concentrations, concentration–response measurements, and cell-quality criteria. These are workflow recommendations rather than numerical findings from the reference study. Record temperature, pH, ionic composition, voltage protocol, exposure time, and washout conditions in the final method because these parameters can influence receptor and channel measurements.

Related reading and scope contrast

The article Perospirone (SM-9018): Unveiling Ion Channel Modulation Beyond Schizophrenia Models frames the compound as a bridge between neuroreceptor pharmacology and vascular ion-channel research. This article extends that framing by separating the published Kv1.5 cellular benchmark from product-level handling information and by stating the in vitro limitations.

The workflow discussion in Perospirone: Applied Workflows for Schizophrenia Research emphasizes experimental utility in schizophrenia research. This article clarifies that receptor affinity data and Kv-channel inhibition arise from different assay systems and should not be combined into a single potency scale.

Conclusion & Outlook

Perospirone, or SM-9018 free base, is a multi-target research compound with reported 5-HT2A and D2 antagonism and 5-HT1A partial agonism. Its receptor profile supports studies of antipsychotic drug mechanism and neuropsychiatric disorder models. The 2025 electrophysiology study adds concentration-dependent vascular Kv-current inhibition and pharmacological evidence implicating Kv1.5 channels.

The most defensible outlook is comparative and mechanistic. Future work can test whether the vascular effect is reproduced in additional vascular preparations, under clearly reported recording conditions, and across clinically relevant exposure ranges. Such work should preserve the distinction between receptor pharmacology, in vitro ion-channel activity, and human clinical evidence. Current data support expanded research use, but they do not justify claims of human cardiovascular efficacy or risk.